Expert Guidance Through Early Inhalation Drug Development
MVIC provides expert support in the pre-clinical development of inhaled drug products. We work closely with our client’s team to generate reliable, early-phase data. Our pre-clinical offering includes in vitro and in vivo testing, inhalation toxicology, pharmacokinetic (PK) modelling, and strategic consultation — all tailored to accelerate your inhalation drug delivery program.
Downloads
Our Services and Capabilities
MVIC supports all aspects of pre-clinical development for inhalation, combining in vitro, in vivo, and strategic consultancy services. Our integrated approach ensures robust data, regulatory alignment, and a clear path forward in your inhalation drug delivery programme.
In Vitro Services
Custom in vitro assays to evaluate mode of action, efficacy, and biomarker response for inhaled therapies.
In Vitro Support for Preclinical Inhalation Studies
As part of our expertise in pre-clinical development for inhalation, MVIC offers a focused range of in vitro services to support early-stage research in inhalation drug delivery. We develop and perform customised cell-based assays, including mode-of-action and efficacy studies, as well as biomarker analysis. Our in vitro capabilities cover primary and immortalised cell lines, air–liquid interface cultures, and pulmonary-specific models — all tailored to reflect the unique requirements of inhaled drug development.
In Vivo Studies
Tailored in vivo studies for pharmacokinetics, efficacy, and toxicology in inhalation drug development
Preclinical In Vivo Testing for Pharmacokinetics, Efficacy and Imaging
MVIC has extensive experience in designing and conducting in vivo studies to support pre-clinical development for inhalation. We offer a range of animal models and administration routes — including inhalation in rodents — with flexible protocols tailored to specific scientific objectives.
Our team generates robust pharmacokinetic (PK) profiles from individual animals and provides full bioanalysis and PK evaluation using Phoenix® WinNonlin®. To strengthen the link between PK and PD, we offer modelling, dose prediction, and development of disease-relevant PD models. In addition, we support imaging studies through modalities such as optical imaging, CT, MRI, and PET, all in close collaboration with our formulation experts to ensure optimal delivery.
Aerosol Delivery and Exposure Systems for Preclinical Inhalation Studies
MVIC offers proven expertise in aerosol delivery for both efficacy and toxicology studies within pre-clinical development for inhalation. We provide advanced inhalation exposure systems — including nose-only and whole-body setups — for both single and repeated dosing.
MVIC use precise aerosol generation and characterisation methods, with integration for DPI, MDI, and nebuliser devices. With full control over particle size and dosing, we enable targeted delivery to specific lung regions and reliable study outcomes.
Strategic Consultancy
We provide expert guidance in pharmacology, translational science, and business development to support your pre-clinical development for inhalation. Our services include protocol design, TPP development, and strategic planning to align studies with regulatory expectations. We also support biomarker strategies, risk mitigation, and translational approaches to strengthen clinical relevance. For early-stage projects, we offer input on market positioning, licensing, and funding strategies — helping you move from concept to competitive opportunity with confidence.
FAQs
Here you’ll find answers to some of the most common questions we receive. Still wondering about something? Feel free to get in touch – we’re happy to tell you more!